Medicare and Medicaid Program; Approval of Application From Det Norske Veritas for Continued Hospital Accreditation Program, 54510-54512 [2022-19099]
Download as PDF
54510
Federal Register / Vol. 87, No. 171 / Tuesday, September 6, 2022 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Medicare & Medicaid
Services
Performance Review Board Members
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice.
The Centers for Disease
Control and Prevention (CDC) located
within the Department of Health and
Human Services (HHS) is publishing the
names of the Performance Review Board
Members who are reviewing
performance of Senior Executive Service
(SES) members, title 42 (T42)
executives, and Senior Level (SL)
employees for Fiscal Year 2022.
FOR FURTHER INFORMATION CONTACT:
Henry Greene, Team Chief, Executive
and Scientific Resources Office, Human
Resources Office, Centers for Disease
Control and Prevention, 11 Corporate
Square Blvd., Mailstop US11–2, Atlanta,
Georgia 30341, Telephone (770) 488–
1140.
Title 5,
U.S.C. 4314(c) (4) of the Civil Service
Reform Act of 1978, Public Law 95–454,
requires that the appointment of
Performance Review Board Members be
published in the Federal Register. The
following persons will serve on the CDC
Performance Review Board, which will
oversee the evaluation of performance
appraisals of Senior Executive Service
members for the Fiscal Year 2022
review period:
jspears on DSK121TN23PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Bornstein, Joshua, Co-Chair
Bonander, Jason
Dulin, Stephanie
Durst, Kelley
Ethier, Kathleen, Co-Chair
Kuhnert, Wendi
Lindsey, Ronney L.
Peeples, Amy
Perry, Terrance
Philip, Celeste M
Tomlinson, Hank
Wharton, Melinda
Dated: August 29, 2022.
Angela K. Oliver,
Executive Secretary, Centers for Disease
Control and Prevention.
[FR Doc. 2022–19177 Filed 9–2–22; 8:45 am]
BILLING CODE 4163–18–P
20:04 Sep 02, 2022
Medicare and Medicaid Program;
Approval of Application From Det
Norske Veritas for Continued Hospital
Accreditation Program
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Final notice.
AGENCY:
SUMMARY:
VerDate Sep<11>2014
[CMS–3424–FN]
Jkt 256001
This final notice announces
our decision to approve Det Norske
Veritas for continued recognition as a
national accrediting organization for
hospitals that wish to participate in the
Medicare or Medicaid programs.
DATES: The decision announced in this
final notice is effective through
September 26, 2026.
FOR FURTHER INFORMATION CONTACT:
Joy Webb, (410) 786–1667.
Lillian Williams, (410) 786–8636.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
Under the Medicare program, eligible
beneficiaries may receive covered
services from a hospital, provided that
certain requirements are met. Section
1861(e) of the Social Security Act (the
Act), establishes distinct criteria for
facilities seeking designation as a
hospital. Regulations concerning
provider agreements are at 42 CFR part
489 and those pertaining to activities
relating to the survey and certification
of facilities are at 42 CFR part 488. The
regulations at 42 CFR part 482 specify
the minimum conditions that a hospital
must meet to participate in the Medicare
program.
Generally, to enter into an agreement,
a hospital must first be certified by a
State survey agency as complying with
the conditions or requirements set forth
in part 482 of our regulations.
Thereafter, the hospital is subject to
regular surveys by a State survey agency
to determine whether it continues to
meet these requirements.
Section 1865(a)(1) of the Act provides
that, if a provider entity demonstrates
through accreditation by an approved
national accrediting organization (AO)
that all applicable Medicare conditions
are met or exceeded, we may deem
those provider entities as having met the
requirements. Accreditation by an AO is
voluntary and is not required for
Medicare participation.
If an AO is recognized by the
Secretary of the Department of Health
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
and Human Services as having
standards for accreditation that meet or
exceed Medicare requirements, any
provider entity accredited by the
national accrediting body’s approved
program may be deemed to meet the
Medicare conditions. A national AO
applying for approval of its
accreditation program under part 488,
subpart A, must provide the Centers for
Medicare and Medicaid Services (CMS)
with reasonable assurance that the AO
requires the accredited provider entities
to meet requirements that are at least as
stringent as the Medicare conditions.
Our regulations concerning the approval
of accrediting organizations are set forth
at § 488.5. The regulations at
§ 488.5(e)(2)(i) require AOs to reapply
for continued approval of its
accreditation program every 6 years or
sooner as determined by CMS. Det
Norske Veritas’s (DNV’s) current term of
approval for their hospital accreditation
program expires September 26, 2022.
II. Application Approval Process
Section 1865(a)(3)(A) of the Act
provides a statutory timetable to ensure
that our review of applications for CMS
approval of an accreditation program is
conducted in a timely manner. The Act
provides us 210 days after the date of
receipt of a complete application, with
any documentation necessary to make
the determination, to complete our
survey activities and application
process. Within 60 days after receiving
a complete application, we must
publish a notice in the Federal Register
that identifies the national accrediting
body making the request, describes the
request, and provides no less than a 30day public comment period. At the end
of the 210-day period, we must publish
a notice in the Federal Register
approving or denying the application.
III. Provisions of the Proposed Notice
On April 18, 2022, we published a
proposed notice in the Federal Register
(87 FR 22894), announcing DNV’s
request for continued approval of its
Medicare hospital accreditation
program. In the proposed notice, we
detailed our evaluation criteria. Under
section 1865(a)(2) of the Act and in our
regulations at § 488.5, we conducted a
review of DNV’s Medicare hospital
accreditation renewal application in
accordance with the criteria specified by
our regulations, which include, but are
not limited to, the following:
• An administrative review of
DNV’s—(1) corporate policies; (2)
financial and human resources available
to accomplish the proposed surveys; (3)
procedures for training, monitoring, and
evaluation of its hospital surveyors; (4)
E:\FR\FM\06SEN1.SGM
06SEN1
Federal Register / Vol. 87, No. 171 / Tuesday, September 6, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES
ability to investigate and respond
appropriately to complaints against
accredited hospitals; and (5) survey
review and decision-making process for
accreditation.
• The comparison of DNV’s Medicare
hospital accreditation program
standards to our current Medicare
hospitals Conditions of Participation
(CoPs).
• A documentation review of DNV’s
survey process to do the following:
++ Determine the composition of the
survey team, surveyor qualifications,
and DNV’s ability to provide continuing
surveyor training.
++ Compare DNV’s processes to those
we require of state survey agencies,
including periodic resurvey and the
ability to investigate and respond
appropriately to complaints against
accredited hospitals.
++ Evaluate DNV’s procedures for
monitoring accredited hospitals it has
found to be out of compliance with
DNV’s program requirements. (This
pertains only to monitoring procedures
when DNV identifies non-compliance. If
noncompliance is identified by a state
survey agency through a validation
survey, the state survey agency monitors
corrections as specified at § 488.9(c)).
++ Assess DNV’s ability to report
deficiencies to the surveyed hospital
and respond to the hospital’s plan of
correction in a timely manner.
++ Establish DNV’s ability to provide
CMS with electronic data and reports
necessary for effective validation and
assessment of the organization’s survey
process.
++ Determine the adequacy of DNV’s
staff and other resources.
++ Confirm DNV’s ability to provide
adequate funding for performing
required surveys.
++ Confirm DNV’s policies with
respect to surveys being unannounced.
++ Confirm DNV’s policies and
procedures to avoid conflicts of interest,
including the appearance of conflicts of
interest, involving individuals who
conduct surveys or participate in
accreditation decisions.
++ Obtain DNV’s agreement to
provide CMS with a copy of the most
current accreditation survey together
with any other information related to
the survey as we may require, including
corrective action plans.
IV. Analysis of and Response to Public
Comments on the Proposed Notice
In accordance with section
1865(a)(3)(A) of the Act, the April 18,
2022 proposed notice also solicited
public comments regarding whether
DNV’s requirements met or exceeded
the Medicare CoPs for hospitals. We
VerDate Sep<11>2014
20:04 Sep 02, 2022
Jkt 256001
received one comment in response to
our proposed notice. The comment
received expressed support for DNV’s
hospital accreditation program.
The proposed notice described CMS’
process and oversight activities in
Section III., Evaluation of Deeming
Authority Request, which highlighted
the evaluation CMS conducts before
granting deeming authority to an AO. In
Section V. of this final notice, CMS is
highlighting areas, which were
identified to have discrepancies or lack
of clarity within DNV’s standards and
survey processes. We note that DNV
corrected these discrepancies prior to
renewal of their deeming authority for
their CMS-approved hospital
accreditation program. CMS continues
to strive for increased oversight of AOs.
V. Provisions of the Final Notice
A. Differences Between DNV’s
Standards and Requirements for
Accreditation and Medicare Conditions
and Survey Requirements
We compared DNV’s hospital
accreditation program requirements and
survey process with the Medicare CoPs
at 42 CFR part 482, and the survey and
certification process requirements of
parts 488 and 489. Our review and
evaluation of DNV’s hospital
application, which were conducted as
described in Section III. of this final
notice, yielded the following areas
where, as of the date of this notice, DNV
has revised its standards and
certification processes in order to meet
our requirements at:
• Section 482.13(e)(8)(i)(A) through
(C). DNV clarified the specific age-based
limits with respect to applicable to the
amount of time a patient could spend in
restraint and seclusion in hospitals;
these limits would supersede any
conflicting state law.
• Section 482.15(a)(1). DNV changed
its standard to include communitybased risk assessment in its
requirements and all-hazards definition
in interpretive guidelines.
• Section 482.15(b)(7). DNV
addressed the requirement that states
make arrangements with others
hospitals and other providers to receive
patients in the event of limitation or
cessation of operations, in order to
maintain the continuity of services to
hospital patients.
• Section 482.23(b)(4). DNV
addressed our concerns pertaining to
nursing assessment and care plan, to
ensure that the requirements are
comparable with CMS’ requirement.
• Sections 482.24(c)(4)(i)(A) through
482.24(c)(4)(i)(C). DNV revised its
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
54511
standards to fully meet CMS
requirements.
• Section 482.28(b)(2). DNV revised
its language from a restrictive
requirement to include an all patient
diet.
• Section 482.41(c). DNV revised
language regarding the applicability of
National Fire Protection Association
(NFPA) to correspond to 2012 NFPA 99,
Section 1.3 Application.
• Section 482.52(c)(2). DNV clarified
the requirement regarding deferral to
state anesthesia practice standards; its
prior language was unclear.
• Section 482.53(d). DNV clarified its
standard regarding nuclear medicine
documentation requirements to include
signed and dated language, showing
authorship.
• Section 482.57. DNV revised its
respiratory care standards to include
language reflecting ‘‘the needs of the
patients’’ in order to fully reflect CMS’
requirement.
• Section 482.58. DNV clarified its
standards to include the governing body
of the hospital bears the responsibility
of assuring medical staff has written
policies.
• Section 482.58(b)(1). DNV revised
the standard to be more specific and to
fully meet the regulatory requirement.
DNV’s standard had not made it clear
that the patients have the right to be
informed of total health status in the
language they can understand, but
rather focused on rules, regulations, and
facility responsibilities during facility
stay.
B. Term of Approval
Based on our review and observations
described in Sections III. and V. of this
final notice, we approve DNV as a
national accreditation organization for
hospitals that request participation in
the Medicare program. The decision
announced in this final notice is
effective September 26, 2022 through
September 26, 2026 (4 years). In
accordance with § 488.5(e)(2)(i), the
term of the approval will not exceed 6
years. Due to travel restrictions and the
reprioritization of survey activities
brought on by the 2019 Novel
Coronavirus Disease (COVID–19) Public
Health Emergency (PHE), CMS was
unable to observe a hospital survey
completed by DNV surveyors as part of
the application review process, which is
typically one component of the
comparability evaluation. Therefore, we
are providing DNV with a shorter period
of approval. Based on our discussions
with DNV and the information provided
in its application, we are confident that
DNV will continue to ensure that its
deemed hospitals continue to meet or
E:\FR\FM\06SEN1.SGM
06SEN1
54512
Federal Register / Vol. 87, No. 171 / Tuesday, September 6, 2022 / Notices
exceed our required standards. While
DNV has taken actions based on the
findings noted in section V.A. of this
final notice (Differences Between TJC’s
Standards and Requirements for
Accreditation and Medicare Conditions
and Survey Requirements), as
authorized under § 488.8, we will
continue ongoing review of DNV’s
hospital surveys. In keeping with CMS’s
initiative to broadly increase AO
oversight, and to ensure that our
requested revisions by DNV are
completed, CMS expects to perform
more frequent review of DNV’s activities
in the future.
VI. Collection of Information
Requirements
This document does not impose
information collection requirements,
that is, reporting, recordkeeping, or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501 et seq.).
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
Chiquita Brooks-LaSure, having
reviewed and approved this document,
authorizes Trenesha Fultz-Mimms, who
is the Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
Trenesha Fultz-Mimms,
Federal Register Liaison, Center for Medicare
& Medicaid Services.
[FR Doc. 2022–19099 Filed 9–2–22; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2022–N–1946]
Pulmonary-Allergy Drugs Advisory
Committee; Notice of Meeting;
Establishment of a Public Docket;
Request for Comments
Food and Drug Administration,
HHS.
Notice; establishment of a
public docket; request for comments.
ACTION:
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Pulmonary-Allergy Drugs
Advisory Committee. The general
function of the committee is to provide
advice and recommendations to FDA on
regulatory issues. The meeting will be
open to the public. FDA is establishing
jspears on DSK121TN23PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:04 Sep 02, 2022
Jkt 256001
The meeting will take place
virtually on November 8, 2022, from 10
a.m. to 4 p.m. eastern time.
ADDRESSES: Please note that due to the
impact of this COVID–19 pandemic, all
meeting participants will be joining this
advisory committee meeting via an
online teleconferencing platform.
Answers to commonly asked questions
about FDA advisory committee meetings
may be accessed at: https://
www.fda.gov/AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
FDA is establishing a docket for
public comment on this meeting. The
docket number is FDA–2022–N–1946.
The docket will close on November 7,
2022. Either electronic or written
comments on this public meeting must
be submitted by November 7, 2022.
Please note that late, untimely filed
comments will not be considered. The
https://www.regulations.gov electronic
filing system will accept comments
until 11:59 p.m. eastern time at the end
of November 7, 2022. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are received
on or before that date.
Comments received on or before
October 25, 2022, will be provided to
the committee. Comments received after
that date will be taken into
consideration by FDA. In the event that
the meeting is cancelled, FDA will
continue to evaluate any relevant
applications or information, and
consider any comments submitted to the
docket, as appropriate.
You may submit comments as
follows:
DATES:
Electronic Submissions
Food and Drug Administration
AGENCY:
a docket for public comment on this
document.
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2022–N–1946 for ‘‘Pulmonary-Allergy
Drugs Advisory Committee; Notice of
Meeting; Establishment of a Public
Docket; Request for Comments.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ FDA
will review this copy, including the
claimed confidential information, in its
consideration of comments. The second
copy, which will have the claimed
confidential information redacted/
blacked out, will be available for public
viewing and posted on https://
www.regulations.gov. Submit both
copies to the Dockets Management Staff.
If you do not wish your name and
contact information be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify the information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
E:\FR\FM\06SEN1.SGM
06SEN1
Agencies
[Federal Register Volume 87, Number 171 (Tuesday, September 6, 2022)]
[Notices]
[Pages 54510-54512]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-19099]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3424-FN]
Medicare and Medicaid Program; Approval of Application From Det
Norske Veritas for Continued Hospital Accreditation Program
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Final notice.
-----------------------------------------------------------------------
SUMMARY: This final notice announces our decision to approve Det Norske
Veritas for continued recognition as a national accrediting
organization for hospitals that wish to participate in the Medicare or
Medicaid programs.
DATES: The decision announced in this final notice is effective through
September 26, 2026.
FOR FURTHER INFORMATION CONTACT:
Joy Webb, (410) 786-1667.
Lillian Williams, (410) 786-8636.
SUPPLEMENTARY INFORMATION:
I. Background
Under the Medicare program, eligible beneficiaries may receive
covered services from a hospital, provided that certain requirements
are met. Section 1861(e) of the Social Security Act (the Act),
establishes distinct criteria for facilities seeking designation as a
hospital. Regulations concerning provider agreements are at 42 CFR part
489 and those pertaining to activities relating to the survey and
certification of facilities are at 42 CFR part 488. The regulations at
42 CFR part 482 specify the minimum conditions that a hospital must
meet to participate in the Medicare program.
Generally, to enter into an agreement, a hospital must first be
certified by a State survey agency as complying with the conditions or
requirements set forth in part 482 of our regulations. Thereafter, the
hospital is subject to regular surveys by a State survey agency to
determine whether it continues to meet these requirements.
Section 1865(a)(1) of the Act provides that, if a provider entity
demonstrates through accreditation by an approved national accrediting
organization (AO) that all applicable Medicare conditions are met or
exceeded, we may deem those provider entities as having met the
requirements. Accreditation by an AO is voluntary and is not required
for Medicare participation.
If an AO is recognized by the Secretary of the Department of Health
and Human Services as having standards for accreditation that meet or
exceed Medicare requirements, any provider entity accredited by the
national accrediting body's approved program may be deemed to meet the
Medicare conditions. A national AO applying for approval of its
accreditation program under part 488, subpart A, must provide the
Centers for Medicare and Medicaid Services (CMS) with reasonable
assurance that the AO requires the accredited provider entities to meet
requirements that are at least as stringent as the Medicare conditions.
Our regulations concerning the approval of accrediting organizations
are set forth at Sec. 488.5. The regulations at Sec. 488.5(e)(2)(i)
require AOs to reapply for continued approval of its accreditation
program every 6 years or sooner as determined by CMS. Det Norske
Veritas's (DNV's) current term of approval for their hospital
accreditation program expires September 26, 2022.
II. Application Approval Process
Section 1865(a)(3)(A) of the Act provides a statutory timetable to
ensure that our review of applications for CMS approval of an
accreditation program is conducted in a timely manner. The Act provides
us 210 days after the date of receipt of a complete application, with
any documentation necessary to make the determination, to complete our
survey activities and application process. Within 60 days after
receiving a complete application, we must publish a notice in the
Federal Register that identifies the national accrediting body making
the request, describes the request, and provides no less than a 30-day
public comment period. At the end of the 210-day period, we must
publish a notice in the Federal Register approving or denying the
application.
III. Provisions of the Proposed Notice
On April 18, 2022, we published a proposed notice in the Federal
Register (87 FR 22894), announcing DNV's request for continued approval
of its Medicare hospital accreditation program. In the proposed notice,
we detailed our evaluation criteria. Under section 1865(a)(2) of the
Act and in our regulations at Sec. 488.5, we conducted a review of
DNV's Medicare hospital accreditation renewal application in accordance
with the criteria specified by our regulations, which include, but are
not limited to, the following:
An administrative review of DNV's--(1) corporate policies;
(2) financial and human resources available to accomplish the proposed
surveys; (3) procedures for training, monitoring, and evaluation of its
hospital surveyors; (4)
[[Page 54511]]
ability to investigate and respond appropriately to complaints against
accredited hospitals; and (5) survey review and decision-making process
for accreditation.
The comparison of DNV's Medicare hospital accreditation
program standards to our current Medicare hospitals Conditions of
Participation (CoPs).
A documentation review of DNV's survey process to do the
following:
++ Determine the composition of the survey team, surveyor
qualifications, and DNV's ability to provide continuing surveyor
training.
++ Compare DNV's processes to those we require of state survey
agencies, including periodic resurvey and the ability to investigate
and respond appropriately to complaints against accredited hospitals.
++ Evaluate DNV's procedures for monitoring accredited hospitals it
has found to be out of compliance with DNV's program requirements.
(This pertains only to monitoring procedures when DNV identifies non-
compliance. If noncompliance is identified by a state survey agency
through a validation survey, the state survey agency monitors
corrections as specified at Sec. 488.9(c)).
++ Assess DNV's ability to report deficiencies to the surveyed
hospital and respond to the hospital's plan of correction in a timely
manner.
++ Establish DNV's ability to provide CMS with electronic data and
reports necessary for effective validation and assessment of the
organization's survey process.
++ Determine the adequacy of DNV's staff and other resources.
++ Confirm DNV's ability to provide adequate funding for performing
required surveys.
++ Confirm DNV's policies with respect to surveys being
unannounced.
++ Confirm DNV's policies and procedures to avoid conflicts of
interest, including the appearance of conflicts of interest, involving
individuals who conduct surveys or participate in accreditation
decisions.
++ Obtain DNV's agreement to provide CMS with a copy of the most
current accreditation survey together with any other information
related to the survey as we may require, including corrective action
plans.
IV. Analysis of and Response to Public Comments on the Proposed Notice
In accordance with section 1865(a)(3)(A) of the Act, the April 18,
2022 proposed notice also solicited public comments regarding whether
DNV's requirements met or exceeded the Medicare CoPs for hospitals. We
received one comment in response to our proposed notice. The comment
received expressed support for DNV's hospital accreditation program.
The proposed notice described CMS' process and oversight activities
in Section III., Evaluation of Deeming Authority Request, which
highlighted the evaluation CMS conducts before granting deeming
authority to an AO. In Section V. of this final notice, CMS is
highlighting areas, which were identified to have discrepancies or lack
of clarity within DNV's standards and survey processes. We note that
DNV corrected these discrepancies prior to renewal of their deeming
authority for their CMS-approved hospital accreditation program. CMS
continues to strive for increased oversight of AOs.
V. Provisions of the Final Notice
A. Differences Between DNV's Standards and Requirements for
Accreditation and Medicare Conditions and Survey Requirements
We compared DNV's hospital accreditation program requirements and
survey process with the Medicare CoPs at 42 CFR part 482, and the
survey and certification process requirements of parts 488 and 489. Our
review and evaluation of DNV's hospital application, which were
conducted as described in Section III. of this final notice, yielded
the following areas where, as of the date of this notice, DNV has
revised its standards and certification processes in order to meet our
requirements at:
Section 482.13(e)(8)(i)(A) through (C). DNV clarified the
specific age-based limits with respect to applicable to the amount of
time a patient could spend in restraint and seclusion in hospitals;
these limits would supersede any conflicting state law.
Section 482.15(a)(1). DNV changed its standard to include
community-based risk assessment in its requirements and all-hazards
definition in interpretive guidelines.
Section 482.15(b)(7). DNV addressed the requirement that
states make arrangements with others hospitals and other providers to
receive patients in the event of limitation or cessation of operations,
in order to maintain the continuity of services to hospital patients.
Section 482.23(b)(4). DNV addressed our concerns
pertaining to nursing assessment and care plan, to ensure that the
requirements are comparable with CMS' requirement.
Sections 482.24(c)(4)(i)(A) through 482.24(c)(4)(i)(C).
DNV revised its standards to fully meet CMS requirements.
Section 482.28(b)(2). DNV revised its language from a
restrictive requirement to include an all patient diet.
Section 482.41(c). DNV revised language regarding the
applicability of National Fire Protection Association (NFPA) to
correspond to 2012 NFPA 99, Section 1.3 Application.
Section 482.52(c)(2). DNV clarified the requirement
regarding deferral to state anesthesia practice standards; its prior
language was unclear.
Section 482.53(d). DNV clarified its standard regarding
nuclear medicine documentation requirements to include signed and dated
language, showing authorship.
Section 482.57. DNV revised its respiratory care standards
to include language reflecting ``the needs of the patients'' in order
to fully reflect CMS' requirement.
Section 482.58. DNV clarified its standards to include the
governing body of the hospital bears the responsibility of assuring
medical staff has written policies.
Section 482.58(b)(1). DNV revised the standard to be more
specific and to fully meet the regulatory requirement. DNV's standard
had not made it clear that the patients have the right to be informed
of total health status in the language they can understand, but rather
focused on rules, regulations, and facility responsibilities during
facility stay.
B. Term of Approval
Based on our review and observations described in Sections III. and
V. of this final notice, we approve DNV as a national accreditation
organization for hospitals that request participation in the Medicare
program. The decision announced in this final notice is effective
September 26, 2022 through September 26, 2026 (4 years). In accordance
with Sec. 488.5(e)(2)(i), the term of the approval will not exceed 6
years. Due to travel restrictions and the reprioritization of survey
activities brought on by the 2019 Novel Coronavirus Disease (COVID-19)
Public Health Emergency (PHE), CMS was unable to observe a hospital
survey completed by DNV surveyors as part of the application review
process, which is typically one component of the comparability
evaluation. Therefore, we are providing DNV with a shorter period of
approval. Based on our discussions with DNV and the information
provided in its application, we are confident that DNV will continue to
ensure that its deemed hospitals continue to meet or
[[Page 54512]]
exceed our required standards. While DNV has taken actions based on the
findings noted in section V.A. of this final notice (Differences
Between TJC's Standards and Requirements for Accreditation and Medicare
Conditions and Survey Requirements), as authorized under Sec. 488.8,
we will continue ongoing review of DNV's hospital surveys. In keeping
with CMS's initiative to broadly increase AO oversight, and to ensure
that our requested revisions by DNV are completed, CMS expects to
perform more frequent review of DNV's activities in the future.
VI. Collection of Information Requirements
This document does not impose information collection requirements,
that is, reporting, recordkeeping, or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.).
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Chiquita Brooks-LaSure, having reviewed and approved this
document, authorizes Trenesha Fultz-Mimms, who is the Federal Register
Liaison, to electronically sign this document for purposes of
publication in the Federal Register.
Trenesha Fultz-Mimms,
Federal Register Liaison, Center for Medicare & Medicaid Services.
[FR Doc. 2022-19099 Filed 9-2-22; 8:45 am]
BILLING CODE 4120-01-P